Diseases of the central nervous system. Pharmacological basis of treatment.
D000547:Amantadine / Q000627:therapeutic use; D000701:Analgesics, Opioid / Q000627:therapeutic use; D000927:Anticonvulsants / Q000627:therapeutic use; D001812:Blood-Brain Barrier; D002493:Central Nervous System Diseases / Q000188:drug therapy*; D002800:Cholinesterase Inhibitors; D004491:Edrophonium / Q000627:therapeutic use; D004827:Epilepsy / Q000188:drug therapy; D006261:Headache / Q000188:drug therapy; D006801:Humans; D007980:Levodopa / Q000627:therapeutic use; D008784:Methysergide / Q000627:therapeutic use; D008881:Migraine Disorders / Q000188:drug therapy; D009157:Myasthenia Gravis / Q000188:drug therapy; D010300:Parkinson Disease / Q000188:drug therapy; D011729:Pyridostigmine Bromide / Q000627:therapeutic use; D012702:Serotonin Antagonists
D000701:Analgesics, Opioid; D000927:Anticonvulsants; D002800:Cholinesterase Inhibitors; D012702:Serotonin Antagonists; D007980:Levodopa; D004491:Edrophonium; D000547:Amantadine; D011729:Pyridostigmine Bromide; D008784:Methysergide